CN110740749B - 在酸性pH下与VISTA结合的抗体 - Google Patents

在酸性pH下与VISTA结合的抗体 Download PDF

Info

Publication number
CN110740749B
CN110740749B CN201880031212.2A CN201880031212A CN110740749B CN 110740749 B CN110740749 B CN 110740749B CN 201880031212 A CN201880031212 A CN 201880031212A CN 110740749 B CN110740749 B CN 110740749B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
light chain
antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880031212.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110740749A (zh
Inventor
R·J·约翰斯顿
A·拉贾帕尔
P·O·谢泼德
L·博尔赫斯
A·兰金
K·S·巴哈特
A·J·科尔曼
A·X·邓
L·H·苏
G·莱克斯特罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Five Prime Therapeutics Inc
Original Assignee
Bristol Myers Squibb Co
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Five Prime Therapeutics Inc filed Critical Bristol Myers Squibb Co
Priority to CN202410878453.8A priority Critical patent/CN118894937A/zh
Publication of CN110740749A publication Critical patent/CN110740749A/zh
Application granted granted Critical
Publication of CN110740749B publication Critical patent/CN110740749B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201880031212.2A 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体 Active CN110740749B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410878453.8A CN118894937A (zh) 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471196P 2017-03-14 2017-03-14
US62/471,196 2017-03-14
US201862636746P 2018-02-28 2018-02-28
US62/636,746 2018-02-28
PCT/US2018/022230 WO2018169993A1 (en) 2017-03-14 2018-03-13 Antibodies binding to vista at acidic ph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410878453.8A Division CN118894937A (zh) 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体

Publications (2)

Publication Number Publication Date
CN110740749A CN110740749A (zh) 2020-01-31
CN110740749B true CN110740749B (zh) 2024-12-10

Family

ID=63522565

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880031212.2A Active CN110740749B (zh) 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体
CN202410878453.8A Pending CN118894937A (zh) 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410878453.8A Pending CN118894937A (zh) 2017-03-14 2018-03-13 在酸性pH下与VISTA结合的抗体

Country Status (18)

Country Link
US (3) US11603406B2 (enExample)
EP (1) EP3595720A4 (enExample)
JP (3) JP7211961B2 (enExample)
KR (2) KR20240151866A (enExample)
CN (2) CN110740749B (enExample)
AU (2) AU2018236218B2 (enExample)
BR (1) BR112019019108A2 (enExample)
CA (1) CA3054067A1 (enExample)
CL (2) CL2019002610A1 (enExample)
CO (1) CO2019010943A2 (enExample)
IL (1) IL269240A (enExample)
MX (1) MX2024003316A (enExample)
MY (1) MY200609A (enExample)
PE (2) PE20191708A1 (enExample)
SG (1) SG11201907848YA (enExample)
TW (2) TWI825010B (enExample)
WO (1) WO2018169993A1 (enExample)
ZA (1) ZA201905525B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BR112013013354A2 (pt) 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
CN113527469A (zh) 2012-02-09 2021-10-22 中外制药株式会社 抗体的Fc区变异体
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
WO2014159562A1 (en) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107108729A (zh) 2015-02-05 2017-08-29 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
PE20191708A1 (es) 2017-03-14 2019-11-28 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
KR20250154550A (ko) 2018-03-21 2025-10-28 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
JP7700036B2 (ja) 2018-07-11 2025-06-30 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡと結合する抗体
MX2021000786A (es) * 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2022003204A (es) * 2019-09-19 2022-04-18 Bristol Myers Squibb Co Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido.
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
IL310292A (en) 2021-07-22 2024-03-01 Univ Dundee Medicinal myotains

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5605821A (en) 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
JP3096305B2 (ja) 1990-07-17 2000-10-10 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ Ｇｍｐ―１４０に対する糖タンパク質リガンド
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
CA2497857C (en) 1992-10-23 2009-05-26 Genetics Institute, Llc Novel p-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP0668907A1 (en) 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995030001A2 (en) 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
CA2230557A1 (en) 1995-09-01 1997-03-13 University Of Washington Interactive molecular conjugates
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002508167A (ja) 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
AU5249700A (en) 1999-07-08 2001-01-30 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
AU2001249421B2 (en) 2000-03-24 2006-09-07 Genetics Institute, Llc A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20060141456A1 (en) 2002-06-12 2006-06-29 Cynthia Edwards Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
UA105492C2 (uk) 2004-05-11 2014-05-26 Абдженомікс Коеператіеф У.А. Спосіб одержання антитіла для викликання смерті активованих т-клітин, спосіб визначення прийнятної сполуки для викликання смерті активованих т-клітин та фармацевтична композиція
EP1781682B1 (en) 2004-06-24 2013-03-13 Mayo Foundation For Medical Education And Research B7-h5, a costimulatory polypeptide
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
WO2006116181A2 (en) 2005-04-25 2006-11-02 Trustees Of Dartmouth College Regulatory t cell mediator proteins and uses thereof
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
EP2086998B1 (en) * 2006-10-11 2011-12-07 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
AU2009212442C1 (en) 2008-02-05 2014-07-17 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
WO2009140623A2 (en) 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
CN102369291A (zh) 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
KR20110136825A (ko) 2009-03-09 2011-12-21 바이오아트라, 엘엘씨 미락 단백질
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
NZ737844A (en) * 2010-03-26 2022-09-30 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
JP6042801B2 (ja) 2010-04-27 2016-12-14 ロシュ グリクアート アーゲー ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
KR20130096731A (ko) * 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
SG11201401735WA (en) * 2011-10-28 2014-05-29 Biogen Idec Internat Neuroscience Gmbh Tdp-43 specific binding molecules
CA2857019C (en) 2011-11-28 2022-08-16 Gray D. Shaw Soluble tandem selectin glycoprotein ligand molecules
CN104379602B (zh) * 2012-03-08 2017-05-03 哈洛齐梅公司 具有条件活性的抗表皮生长因子受体抗体及其使用方法
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) * 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
KR20160129698A (ko) 2013-05-24 2016-11-09 메디뮨 엘엘씨 항-b7-h5 항체 및 이의 용도
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
MY182431A (en) * 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
AU2015206189B2 (en) 2014-01-14 2019-06-20 Kings College London VISTA antagonist and methods of use
RU2550262C1 (ru) 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
EP3152222A4 (en) 2014-06-04 2017-11-01 NGM Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
CN106659784B (zh) 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
AU2015360282B2 (en) 2014-12-11 2021-04-01 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
MX2017015041A (es) * 2015-05-29 2018-02-26 Squibb Bristol Myers Co Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
RU2735023C9 (ru) 2015-11-02 2021-06-18 Биоатла, Ллс Условно активные полипептиды
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
PH12018502203B1 (en) * 2016-04-15 2024-05-15 Immunext Inc Anti-human vista antibodies and use thereof
EP3494141A4 (en) 2016-08-03 2020-04-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
PE20191708A1 (es) 2017-03-14 2019-11-28 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
WO2018195772A1 (en) 2017-04-25 2018-11-01 Sun Yat-Sen University Pd-1h as target in treatement of asthma
WO2018237287A1 (en) 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
EP3699193A4 (en) 2017-10-20 2022-01-26 Pharmabcine Inc. ANTI-VISTA ANTIBODIES AND USE THEREOF
WO2019087092A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US20210085785A1 (en) 2018-02-23 2021-03-25 Truebinding, Inc. Treating cancer by blocking the interaction of vista and its binding partner
KR20250154550A (ko) * 2018-03-21 2025-10-28 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2019185163A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Vista antigen-binding molecules
JP7700036B2 (ja) 2018-07-11 2025-06-30 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡと結合する抗体
CN109878421B (zh) 2019-03-13 2020-11-03 浙江吉利控股集团有限公司 车辆坡道装置及汽车
CN110563843A (zh) 2019-07-25 2019-12-13 钟小泉 一种靶向人vista蛋白的单克隆抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A New VISTA on combination therapy for negative checkpoint regulator blockade;Jie Deng;《Journal for Immunotherapy of Cancer》;第第4卷卷(第第4卷期);第1-7页 *
Jie Deng.A New VISTA on combination therapy for negative checkpoint regulator blockade.《Journal for Immunotherapy of Cancer》.2016,第第4卷卷(第第4卷期),第1-7页. *

Also Published As

Publication number Publication date
TWI890190B (zh) 2025-07-11
JP2025023919A (ja) 2025-02-19
AU2018236218B2 (en) 2025-03-06
US20250206822A1 (en) 2025-06-26
US20240092907A1 (en) 2024-03-21
MX2024003316A (es) 2024-04-04
EP3595720A4 (en) 2021-05-26
JP2020509756A (ja) 2020-04-02
EP3595720A1 (en) 2020-01-22
US20200055936A1 (en) 2020-02-20
TWI825010B (zh) 2023-12-11
CO2019010943A2 (es) 2020-01-17
KR20190128198A (ko) 2019-11-15
CN118894937A (zh) 2024-11-05
TW202423986A (zh) 2024-06-16
JP7211961B2 (ja) 2023-01-24
US11603406B2 (en) 2023-03-14
KR20240151866A (ko) 2024-10-18
TW201843171A (zh) 2018-12-16
CL2019002610A1 (es) 2019-11-29
KR102715540B1 (ko) 2024-10-08
JP7573659B2 (ja) 2024-10-25
AU2025203967A1 (en) 2025-07-03
ZA201905525B (en) 2024-12-18
IL269240A (en) 2019-11-28
CN110740749A (zh) 2020-01-31
MY200609A (en) 2024-01-05
BR112019019108A2 (pt) 2020-04-22
JP2023061927A (ja) 2023-05-02
SG11201907848YA (en) 2019-09-27
CL2021002769A1 (es) 2022-08-12
CA3054067A1 (en) 2018-09-20
AU2018236218A1 (en) 2019-09-12
PE20191708A1 (es) 2019-11-28
WO2018169993A1 (en) 2018-09-20
PE20250933A1 (es) 2025-04-02
US12195535B2 (en) 2025-01-14

Similar Documents

Publication Publication Date Title
CN110740749B (zh) 在酸性pH下与VISTA结合的抗体
KR102874694B1 (ko) 산성 pH에서 VISTA에 결합하는 항체
JP7700036B2 (ja) 酸性ｐＨでＶＩＳＴＡと結合する抗体
KR20220065816A (ko) 산성 pH에서 VISTA에 결합하는 항체
CN121203021A (zh) 在酸性pH下结合至VISTA的抗体
EA042790B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment